Unicycive Therapeutics, Inc. (UNCY) Stock

Unicycive Therapeutics, Inc. (UNCY) is a Healthcare stock trading at $5.63 (as of 2026-08-21), with a market capitalization of $150.32M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Unicycive Therapeutics, Inc. is a biotechnology company developing therapies for kidney conditions in the United States. Its pipeline includes Renazorb for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury.

Understand Unicycive Therapeutics, Inc.: how it makes money

Unicycive Therapeutics is a biotech company developing kidney disease treatments, including Renazorb for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury, and it is making money only if these therapies progress toward commercialization (current provided facts focus on development rather than a specific revenue source).

Because Unicycive has therapy candidates in development (Renazorb and UNI 494), its profit engine is primarily tied to clinical progress and treatment acceptance that support future commercialization, and the provided latest-quarter financials show no revenue.

Business quality (Weak): Development-stage profile is supported by the provided quarterly revenue of 0.0B and very negative operating margin, while the operational KPIs focus on clinical and patient-reported outcomes (phosphate control, ease to take, preference, and discontinuation due to adverse events).

Bull case

  • Strong phosphate-control outcome at end of titration: Patients Achieving Serum Phosphate Level at End of Titration (≤44.5 mg/dL) is 90%.
  • High patient-reported acceptability for oxylanthanum carbonate: Patients Reporting Oxylanthanum Carbonate Was Easy to Take is 98%, and Patients Satisfied with Oxylanthanum Carbonate is 89%.
  • Preference versus prior therapy: Patient Preference for Oxylanthanum Carbonate over Prior Therapy is 79%.

Bear case

  • Treatment-related tolerability signals: Discontinuation Rate Due to Treatment-Related Adverse Events is 6%, and treatment-related diarrhea incidence is 9% (vomiting incidence is 6%).
  • No revenue shown in the latest provided quarter: For the period ended 2026-03-31, provided revenue is 0.0B, consistent with limited commercial contribution in the information given.
Valuation — source: SEC EDGAR (first-party)
Price$5.63
Market Cap$150.32M
Price / Book2.82
Price / Sales99.68
FCF Yield-33.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.01M
Net Margin-2624.0%
Revenue Growth (YoY)-19.7%
EPS Growth (YoY)198.2%
FCF Growth (YoY)9.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.37 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVivo Capital, LLC ($11.78M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOShalabh K. Gupta
Employees22
CountryUS
IPO Date2021-07-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Lifecore Biomedical, Inc. (LFCR)
  • Indaptus Therapeutics, Inc. (INDP)
  • OnKure Therapeutics, Inc. (OKUR)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Assertio Holdings, Inc. (ASRT)
  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Equillium, Inc. (EQ)
  • Spruce Biosciences, Inc. (SPRB)
UNCY earnings history · UNCY institutional & insider holders · UNCY KPIs & operating metrics · UNCY financials · UNCY investor presentations & press releases · UNCY SEC filings · UNCY peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.